Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders

Clinical trial NCT05403138 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05403138
Sponsor: Tianjin Medical University General Hospital
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Neuromyelitis Optica Neuromyelitis Optica Spectrum Disorder NMO Spectrum Disorder

Start date: 2022-11-01
Primary completion: 2025-11-01
Enrollment: 135

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.